ArticleBioinformatics (Oxford, England)2025
TCR-epiDiff: solving dual challenges of TCR generation and binding prediction.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mitigating negative data bias to enhance TCR-epitope binding and residue interaction prediction.Briefings in bioinformatics · 2026Article
- Modeling TCR-Epitope Recognition Specificity: What We Should Learn to Succeed.Immunological reviews · 2026Review
- Mapping the TCR landscape: computational tools empowering translational immunology and therapy design.Journal for immunotherapy of cancer · 2026Review
- Peptide-based drug design using generative AI.Chemical communications (Cambridge, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
motivationT cell receptors (TCRs) are fundamental components of the adaptive immune system, recognizing specific antigens for targeted immune responses. Understanding their sequence patterns is crucial for designing effective vaccines and immunotherapies. However, the vast diversity of TCR sequences and complex binding mechanisms pose significant challenges in generating TCRs that are specific to a particular epitope.
resultsHere, we propose TCR-epiDiff, a diffusion-based deep learning model for generating epitope-specific TCRs and predicting TCR-epitope binding. TCR-epiDiff integrates epitope information during TCR sequence embedding using ProtT5-XL and employs a denoising diffusion probabilistic model for sequence generation. Using external validation datasets, we demonstrate the ability to generate biologically plausible, epitope-specific TCRs. Furthermore, we leverage the model's encoder to develop a TCR-epitope binding predictor that shows robust performance on the external validation data. Our approach provides a comprehensive solution for both de novo generation of epitope-specific TCRs and TCR-epitope binding prediction. This capability provides valuable insights into immune diversity and has the potential to advance targeted immunotherapies. AVAILABILITY AND IMPLEMENTATION: The data and source codes for our experiments are available at: https://github.com/seoseyeon/TCR-epiDiff.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.